In a 34-year-old Indian woman with intermittent chest pain on recumbence, right-leg calf cramps, and a tibia/fibula intramedullary rod placed seven years ago, who has been using an ethinylestradiol-containing combined oral contraceptive for one month, should she continue the contraceptive?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

No, she should discontinue the ethinylestradiol-containing contraceptive immediately.

This patient presents with concerning symptoms that raise significant red flags for venous thromboembolism (VTE): intermittent chest pain on recumbence and right-leg calf cramps while on a combined hormonal contraceptive (CHC). These symptoms warrant immediate discontinuation of the ethinylestradiol-containing oral contraceptive and urgent evaluation for VTE. 1

Critical Risk Factors Present

This 34-year-old woman has multiple concerning features:

  • Active symptoms suggestive of possible VTE: Chest pain (potential pulmonary embolism) and unilateral leg cramps (potential deep vein thrombosis)
  • Recent immobilization history: Tibia/fibula intramedullary rod placement 7 years ago suggests prior significant trauma/surgery
  • Current CHC use: Only one month into therapy, which is the highest-risk period for VTE

The FDA labeling explicitly states that CHCs should be stopped if an arterial or venous thrombotic/thromboembolic event occurs or is suspected. 1 The combination of chest pain and unilateral leg symptoms in a CHC user constitutes a medical emergency requiring immediate evaluation.

Why Discontinuation is Mandatory

VTE Risk with CHCs

Combined oral contraceptives increase VTE risk to 3-9 cases per 10,000 woman-years, with the highest risk occurring during the first year of use. 1 The FDA drug label emphasizes that risk is particularly elevated when:

  • Starting CHCs for the first time (this patient is at 1 month)
  • Restarting after a break of 4+ weeks
  • In the presence of additional risk factors

Contraindications to Continuation

The FDA labeling is unequivocal: "Stop levonorgestrel and ethinyl estradiol tablets if an arterial or venous thrombotic/thromboembolic event occurs." 1 While diagnostic confirmation is pending, the clinical presentation warrants immediate cessation as a precautionary measure.

Immediate Management Algorithm

  1. Discontinue the CHC immediately - do not wait for diagnostic confirmation
  2. Urgent imaging evaluation:
    • Duplex ultrasonography of the right leg for DVT assessment 2
    • CT pulmonary angiography (CTPA) if PE is suspected based on chest pain characteristics 2
  3. If VTE is confirmed: Initiate anticoagulation therapy
  4. If VTE is excluded: Still do not restart CHC; consider alternative contraception

Alternative Contraception Options

Given this clinical scenario, safer alternatives include:

  • Levonorgestrel intrauterine system (LNG-IUD): No increased VTE risk, highly effective 2
  • Copper IUD: Hormone-free option
  • Progestin-only methods: Implant or progestin-only pills (though still requires careful consideration if VTE confirmed)
  • Barrier methods: Condoms as immediate backup

Critical Pitfalls to Avoid

Do not continue CHC "to see if symptoms resolve" - this is the most dangerous error. The symptoms described are classic warning signs that mandate immediate action. The 2024 CDC guidelines emphasize that while CHCs can be started liberally in healthy women, they must be stopped promptly when thrombotic events are suspected. 3

Do not assume the intramedullary rod from 7 years ago is irrelevant - while remote, any history of significant lower extremity trauma/surgery combined with current symptoms and CHC use creates a concerning clinical picture.

The chest pain "on recumbence" pattern does not exclude PE - positional chest pain can occur with PE, particularly with smaller emboli or pleural involvement.

Post-Evaluation Considerations

Even if imaging rules out acute VTE, this patient should not resume ethinylestradiol-containing contraceptives. The symptom complex suggests she may have underlying risk factors (possibly undiagnosed thrombophilia) that make CHCs inappropriate. Consider thrombophilia workup if VTE is confirmed, though this should not delay anticoagulation. 2

The priority is preventing potentially fatal pulmonary embolism or progression of DVT, not maintaining this specific contraceptive method. Multiple effective alternatives exist that do not carry the same thrombotic risk.

References

3
Guideline

u.s. selected practice recommendations for contraceptive use, 2024.

MMWR Recommendations and Reports, 2024

Related Questions

What is the appropriate management for a 25-year-old female with non‑traumatic pressure‑like chest pain radiating to the right shoulder, mid‑back, and neck, associated neck tightness, pain 5/10, no red‑flag symptoms, and a history of cholecystectomy?
In a 42-year-old man with chest pain worsened by deep breathing, chest wall tenderness, and palpitations, what is the appropriate diagnostic workup and initial management?
What is the appropriate initial evaluation and management for a 61-year-old male presenting with chest pain and a history of coronary artery disease?
How should I evaluate and manage a 66-year-old woman with intermittent burning chest pain for two weeks, exertional shortness of breath, regular heart rhythm, no murmurs/rubs/gallops, clear lungs, negative troponin, and who has stopped all chronic medications including antihypertensives?
What is the appropriate initial management for a 22-year-old female presenting with chest pain?
Should the bupropion (Wellbutrin) be reduced to 150 mg daily or discontinued in a patient who became suicidal on 300 mg but was stable on 150 mg, given that the patient refuses selective serotonin reuptake inhibitors (SSRIs)?
What medications are most appropriate for treating post-concussion headache in an 18-year-old male without a history of migraine?
Can baloxavir (baloxavir marboxil) be taken concurrently with acetaminophen?
What is the therapeutic plasma concentration range for vilazodone?
How do I order a urea breath test (UBT) or Helicobacter pylori stool antigen (HpSA) through the laboratory?
What are the postoperative instructions after a tooth extraction?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.